Global Hashimoto’s Disease Market, By Type (Stress Related, Infection Related, Autoimmune Related, Environmental Related, Disease Related, Mixed, Others), Treatment (T-3 Hormone Replacement Therapy, T-4 Hormone Replacement Therapy, Others), Dosage Form (Tablets, Capsule, Powder, Others), Route of Administration (Oral, Parenteral, Others), Diagnosis (Antibody Tests, Testing Thyroid Function, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
In recent years, the Hashimoto’s disease market is anticipated to grow rapidly during the forecast period. The recommended daily intake (RDI) of iodine, according to the World Health Organization (WHO), is 150 mcg per day, which is sufficient for more than 95 percent of all healthy individuals, with pregnant and lactating women requiring more. Excessive intake of iodine is the major reason that act as trigger for people who are already at the risk of Hashimoto’s disease. Hashimoto disease is a thyroid gland illness that affects many people. It can strike anyone at any age, but it is most common in middle-aged women. It is caused by the immune system's attack on the thyroid gland. It can take months or even years to diagnose the disease and for thyroid hormone levels to drop below normal. People with a family history of thyroid dysfunction are more likely to develop Hashimoto disease.
Data Bridge Market Research analyses that the Hashimoto’s disease market was valued at USD 973.69 million in 2021 and is expected to reach USD 1,282.16 million by 2029, registering a CAGR of 3.50% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Hashimoto's illness is a condition that affects the thyroid gland. Hashimoto's disease is also known as chronic lymphocytic thyroiditis, Hashimoto's thyroiditis or autoimmune thyroiditis. The thyroid gland produces hormones that regulate and maintain nearly all of the body's metabolic activities (how it converts food into energy). Hashimoto's thyroiditis is an autoimmune condition in which your immune system misidentifies your thyroid and affects it.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Stress Related, Infection Related, Autoimmune Related, Environmental Related, Disease Related, Mixed, Others), Treatment (T-3 Hormone Replacement Therapy, T-4 Hormone Replacement Therapy, Others), Dosage Form (Tablets, Capsule, Powder, Others), Route of Administration (Oral, Parenteral, Others), Diagnosis (Antibody Tests, Testing Thyroid Function, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Cipla Inc. (US), Abbott (US), AbbVie Inc. (US), Merck KGaA (Germany), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Provell Pharmaceuticals, LLC (US), Alvogen (US), Piramal Enterprises Ltd. (US), Dr. Reddy’s Laboratories Ltd. (India), Pfizer Inc. (US), Fresenius Kabi AG (Germany), Bio-Rad Laboratories, Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland)
|
|
Market Opportunities
|
|
Hashimoto’s Disease Market Dynamics
Drivers
- Increasing prevalence of hypothyroidism
The rising prevalence of hypothyroidism is estimated to enhance the Hashimoto’s disease market's growth. When the thyroid gland is injured by the immune system, it cannot produce enough thyroid hormones to meet the body's needs, resulting in Hashimoto's hypothyroidism. Thyroid hormones control metabolism, which is the process of converting food into energy.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of Hashimoto’s disease market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Growing number of geriatric population
The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to get Hashimoto’s disease, further estimated to enhance the market’s growth rate.
- Surging incidences of autoimmune disease
The increasing incidences of autoimmune disease is anticipated to influence the growth of Hashimoto’s disease market. Rheumatoid arthritis, lupus and type 1 diabetes are among the various autoimmune disease that increases the risk of Hashimoto’s disease and further flourish the markets growth during the forecast period of 2022-2029.
Furthermore, rising initiatives by public and private organizations to spread awareness and family history with thyroid diseases will expand the Hashimoto’s disease market. Additionally, rising radiation exposure and high consumption alcohol and alcohol will result in the expansion of Hashimoto’s disease market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the Hashimoto’s disease market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the Hashimoto’s disease market growth during the forecast period.
Restraints/Challenges
On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the Hashimoto’s disease market. Additionally, strict regulatory policies and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This Hashimoto’s disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Hashimoto’s disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
In the United States, Hashimoto's disease is the most frequent cause of hypothyroidism, affecting around 5% of the population. It affects mostly adult females and usually appears between the ages of 40 and 60. Females are at least 8 times more likely than males to be affected.
Hashimoto’s disease market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Hashimoto’s Disease Market
Over the projected period, the Hashimoto’s disease market was expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in a number of nations had imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The Hashimoto’s disease market has also been hampered by the supply chain slowness.
Global Hashimoto’s Disease Market Scope
The Hashimoto’s disease market is segmented on the basis of type, treatment, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Stress Related
- Infection Related
- Autoimmune Related
- Environmental Related
- Disease Related
- Mixed
- Others
Treatment
- T-3 Hormone Replacement Therapy
- T-4 Hormone Replacement Therapy
- Others
Diagnosis
- Antibody Tests
- Testing Thyroid Function
- Thyroxine (T-4) Test
- Thyroid Stimulating Hormone (TSH) Test
- Others
Dosage form
- Tablets
- Capsule
- Powder
- Others
Route of Administration
- Oral
- Topical
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Hashimoto’s Disease Market Regional Analysis/Insights
The Hashimoto’s disease market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Hashimoto’s disease market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the Hashimoto’s disease market because of the growing number of research and development in autoimmune disorders and rising healthcare expenditure in this region. Additionally, the presence of major key players will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period due to rising population and surging number of generic manufacturers in this region. Also, development of healthcare infrastructure will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Hashimoto’s Disease Market Share Analysis
The Hashimoto’s disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Hashimoto’s disease market.
Some of the major players operating in the Hashimoto’s disease market are:
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (US)
- Merck & Co., Inc. (US)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- Cipla Inc. (US)
- Abbott (US)
- AbbVie Inc. (US)
- Merck KGaA (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Provell Pharmaceuticals, LLC (US)
- Alvogen (US)
- Piramal Enterprises Ltd. (US)
- Dr. Reddy’s Laboratories Ltd. (India)
- Pfizer Inc. (US)
- Fresenius Kabi AG (Germany)
- Bio-Rad Laboratories, Inc. (US)
- Takeda Pharmaceutical Company Limited (Japan)
- Sanofi (France)
- F. Hoffmann-La Roche Ltd. (Switzerland)
SKU-